Unilever PLC says ceramide technology already being used in its Vaseline Total Moisture and Dove Deeply Nourishing Body Wash could be the basis for new products across brands in light of research showing microbiome benefits.
Unilever Says Findings On Microbiome-Boosting Lipid Technology Will Fuel Product Innovation
Unilever’s research partnerships are paying off, yielding microbiome findings that are accelerating the firm’s innovation pipeline, with new products envisioned for treating scalp, underarms and oral health in addition to skin, the firm says.
More from Innovation & IP
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
Bayer Consumer Health hopes its new InflammAge saliva-based biomarker can help “revolutionize self-care and how people can manage their aging journey.”
• By
HBW Insight catches up with Maxwellia CEO Anna Maxwell to discuss her company's journey so far, and what she sees as the opportunities for Rx-to-OTC switch in UK women's health and beyond.
• By
Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”
More from Health
• By
FDA testing of 95 benzoyl peroxide products due to concerns about elevated benzene detected by third-party testers found 90% with undetectable or extremely low benzene levels.
• By
“Overall, no unexpected/new data or findings” were presented to Germany's Expert Committee for Prescription in the most recent Rx-to-OTC switch application for sildenafil (25mg and 50mg), according to medicines regulator BfArM, resulting in a third rejection in three years.
• By
Galenica outpaced the growth of the OTC market at home, while recording a double-digit gain abroad, to drive up its consumer health product sales in 2024.